| Replagal (agalsidase alfa) / Samaritan Pharma, Takeda |
NCT01196871 / 2010-022709-16: Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease |
|
|
| Completed | 2a | 20 | Canada, US, Europe, RoW | Migalastat HCl, AT1001, Galafold, migalastat, Agalsidase Beta, Fabrazyme, Agalsidase Alfa, Replagal | Amicus Therapeutics | Fabry Disease | 10/12 | 10/12 | | |
NCT00048906: Alpha-Galactosidase A Replacement Therapy for Fabry Disease |
|
|
| Completed | 2 | 3 | US | DRX005B | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 11/03 | | |
NCT00071877: An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease |
|
|
| Completed | 2 | 25 | US | Replagal | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 06/05 | | |
NCT00075244: Alternative Dosing and Regimen of Replagal to Treat Fabry Disease |
|
|
| Completed | 2 | 25 | US | Replagal | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | | 11/05 | | |
NCT00068107: Dosing Study of Replagal in Patients With Fabry Disease |
|
|
| Completed | 2 | 13 | US | Replagal, agalsidase alfa | Baylor Research Institute, National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | 12/13 | 12/13 | | |
